Correction: Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma.
Journal: BMC Medicine
Published:
Authors
Miaoyan Wei, Rujiao Liu, Yunyun Xu, Xiaobing Chen, Chao Liu, Xueli Bai, Xiaochen Zhang, Shuiping Gao, Jialin Li, Zhen Sheng, Jianpo Lian, Wenliang Wang, Jian Zhang, Si Shi, Jin Xu, Xianjun Yu
Relevant Conditions